Preliminary Evaluation of Human Immunodeficiency Virus Type 1 (HIV-1) Immunogen in Children with HIV-1 Infection

The safety and preliminary activity of human immunodeficiency virus type 1 (HIV-1) immunogen were evaluated in 10 HIV-1—infected children with disease stage N1,2 or A1,2. Multiple inoculations of 2.5 or 10 units (U) of HIV-1 immunogen were safe and well tolerated without an acceleration of disease progression. When antiretroviral agents were coadministered, the 10 U dose appeared to be associated with more sustained reduction in plasma HIV-1 RNA than the 2.5 U dose (median log10 HIV-1 RNA at month 18, 3.07 vs. 4.01 copies/mL in 10 U [n = 4 ] vs. 2.5 U [n = 3], respectively; P = .034). Levels of regulated-on-activation, normal T cell—expressed and —secreted chemokine produced from HIV-1 immunogen—stimulated lymphocytes in vitro were increased in the children who had HIV-1 immunogen—specific antibody responses (P < .02) and appeared to be inversely correlated with levels of plasma HIV-1 RNA (P < .01). These preliminary data warrant larger studies to determine the effectiveness of adjunctive therapy with HIV-1 immunogen in children with HIV-1 infection.